[{"id":"2f7de6f9-5668-4b83-820d-b62ff50be145","acronym":"","url":"https://clinicaltrials.gov/study/NCT04445064","created_at":"2021-06-23T19:54:36.637Z","updated_at":"2025-02-25T16:15:55.863Z","phase":"Phase 2","brief_title":"Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck.","source_id_and_acronym":"NCT04445064","lead_sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cylembio (imsapepimut and etimupepimut, adjuvanted) • IO102"],"overall_status":"Recruiting","enrollment":" Enrollment 17","initiation":"Initiation: 08/14/2020","start_date":" 08/14/2020","primary_txt":" Primary completion: 06/08/2024","primary_completion_date":" 06/08/2024","study_txt":" Completion: 06/08/2024","study_completion_date":" 06/08/2024","last_update_posted":"2022-05-12"}]